X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3119) 3119
Book Chapter (31) 31
Magazine Article (12) 12
Publication (12) 12
Dissertation (9) 9
Conference Proceeding (4) 4
Book / eBook (1) 1
Newsletter (1) 1
Reference (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
natalizumab (2832) 2832
humans (2148) 2148
multiple sclerosis (1666) 1666
clinical neurology (1275) 1275
female (1058) 1058
male (892) 892
adult (872) 872
progressive multifocal leukoencephalopathy (840) 840
multiple sclerosis - drug therapy (795) 795
neurosciences (732) 732
middle aged (629) 629
antibodies, monoclonal, humanized (529) 529
multiple sclerosis, relapsing-remitting - drug therapy (505) 505
antibodies, monoclonal - therapeutic use (492) 492
neurology (482) 482
antibodies, monoclonal, humanized - therapeutic use (433) 433
treatment outcome (415) 415
magnetic resonance imaging (383) 383
immunologic factors - therapeutic use (382) 382
therapy (378) 378
multiple-sclerosis (375) 375
placebo-controlled trial (325) 325
immunosuppressive agents - therapeutic use (319) 319
fingolimod (318) 318
immunology (313) 313
natalizumab - therapeutic use (302) 302
glatiramer acetate (288) 288
antibodies, monoclonal - adverse effects (284) 284
drug therapy (265) 265
jc virus (263) 263
care and treatment (258) 258
young adult (258) 258
animals (257) 257
leukoencephalopathy, progressive multifocal - chemically induced (256) 256
disease (249) 249
double-blind (247) 247
pharmacology & pharmacy (247) 247
risk (247) 247
abridged index medicus (241) 241
antibodies, monoclonal, humanized - adverse effects (234) 234
multiple sclerosis - immunology (228) 228
risk factors (224) 224
patients (222) 222
immunologic factors - adverse effects (205) 205
medicine & public health (205) 205
research (194) 194
interferon (191) 191
disease progression (189) 189
rituximab (181) 181
adolescent (178) 178
recurrence (177) 177
natalizumab - adverse effects (174) 174
alemtuzumab (170) 170
interferon beta-1a (170) 170
monoclonal antibodies (169) 169
psychiatry (169) 169
interferon-beta - therapeutic use (167) 167
brain - pathology (166) 166
retrospective studies (164) 164
disability (163) 163
crohn's disease (162) 162
efficacy (162) 162
health aspects (162) 162
medicine, general & internal (160) 160
pml (160) 160
aged (156) 156
antibodies (148) 148
infliximab (148) 148
cerebrospinal-fluid (147) 147
disability evaluation (147) 147
interferon-beta (147) 147
follow-up studies (145) 145
immunosuppressive agents - adverse effects (142) 142
crohn disease - drug therapy (139) 139
leukoencephalopathy, progressive multifocal - diagnosis (138) 138
disease-activity (137) 137
analysis (136) 136
oral fingolimod (136) 136
multiple sclerosis - pathology (135) 135
multiple sclerosis - therapy (135) 135
gastroenterology & hepatology (133) 133
jc virus - immunology (133) 133
time factors (132) 132
clinical trials (130) 130
lymphocytes (130) 130
diagnosis (129) 129
infection (129) 129
multiple sclerosis - diagnosis (129) 129
controlled trial (127) 127
multicenter (126) 126
relapsing multiple-sclerosis (126) 126
inflammation (125) 125
safety (125) 125
leukoencephalopathy (120) 120
trial (114) 114
expression (113) 113
integrin (112) 112
medical research (112) 112
brain (111) 111
leukoencephalopathy, progressive multifocal (111) 111
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2831) 2831
German (113) 113
French (83) 83
Spanish (64) 64
Russian (20) 20
Czech (17) 17
Japanese (16) 16
Portuguese (14) 14
Hungarian (12) 12
Polish (6) 6
Norwegian (5) 5
Swedish (4) 4
Danish (3) 3
Finnish (3) 3
Italian (3) 3
Chinese (2) 2
Croatian (2) 2
Dutch (2) 2
Icelandic (1) 1
Korean (1) 1
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


International journal of molecular sciences, ISSN 1422-0067, 2017, Volume 18, Issue 5, p. 940
Journal Article
Journal Article
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 01/2019, Volume 321, Issue 2, pp. 175 - 187
Journal Article
Brain, ISSN 0006-8950, 11/2015, Volume 138, Issue 11, pp. 3275 - 3286
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 08/2018, Volume 2018, Issue 8, p. CD006097
Background This systematic review update summarizes the current evidence on the use of natalizumab for induction of remission in Crohn's disease (CD).... 
Immunologic Factors | Integrin alpha4 | Natalizumab | Gastroenterology & hepatology | Crohn Disease | Induction Chemotherapy | Antibodies, Monoclonal | Patient Dropouts | Randomized Controlled Trials as Topic | Crohn's disease: induction of remission | Inflammatory bowel disease | Antibodies, Monoclonal, Humanized | CROHN'S DISEASE ‐ INDUCTION OF REMISSION | Infliximab | Treatment Failure | Medicine General & Introductory Medical Sciences | Gastrointestinal Agents | Integrins | SUSTAINED RESPONSE | RECOMBINANT HUMANIZED ANTIBODY | Treatment Failure Humans | Remission Induction | MAINTENANCE THERAPY | MEDICINE, GENERAL & INTERNAL | Antibodies, Monoclonal [administration & dosage; therapeutic use] | COTTON-TOP TAMARIN | PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY | INFLAMMATORY-BOWEL-DISEASE | Crohn Disease [drug therapy] | Integrins [antagonists & inhibitors] | QUALITY-OF-LIFE | PLACEBO-CONTROLLED TRIAL | ALPHA-4 INTEGRIN | CLINICAL-RESPONSE | Patient Dropouts - statistics & numerical data | Humans | Natalizumab - adverse effects | Gastrointestinal Agents - administration & dosage | Immunologic Factors - administration & dosage | Antibodies, Monoclonal - therapeutic use | Infliximab - therapeutic use | Infliximab - administration & dosage | Antibodies, Monoclonal - administration & dosage | Crohn Disease - drug therapy | Natalizumab - administration & dosage | Natalizumab - therapeutic use | Gastrointestinal Agents - therapeutic use | Immunologic Factors - adverse effects | Integrins - antagonists & inhibitors | Immunologic Factors - therapeutic use
Journal Article
PloS one, ISSN 1932-6203, 2017, Volume 12, Issue 2, p. e0170395
Journal Article
Drugs, ISSN 0012-6667, 10/2017, Volume 77, Issue 16, pp. 1755 - 1768
Since the approval of fingolimod, several selective sphingosine-1-phosphate receptor modulators have entered clinical development for multiple sclerosis.... 
Pharmacotherapy | Internal Medicine | Medicine & Public Health | Pharmacology/Toxicology | LONG-TERM | BAF312 SIPONIMOD | TUMEFACTIVE MS | EFFICACY | ORAL FINGOLIMOD FTY720 | DOUBLE-BLIND | PHARMACOLOGY & PHARMACY | OPEN-LABEL | TOXICOLOGY | DISEASE-MODIFYING THERAPIES | SAFETY PROFILE | FREEDOMS II | Fingolimod Hydrochloride - pharmacology | Multiple Sclerosis - diagnosis | Risk Assessment | Humans | Natalizumab - adverse effects | Natalizumab - chemistry | Natalizumab - pharmacology | Fingolimod Hydrochloride - chemistry | Natalizumab - administration & dosage | Multiple Sclerosis - immunology | Immunosuppressive Agents - adverse effects | Receptors, Lysosphingolipid - metabolism | Fingolimod Hydrochloride - adverse effects | Immunosuppressive Agents - pharmacology | Immunosuppressive Agents - administration & dosage | Immunosuppressive Agents - chemistry | Fingolimod Hydrochloride - administration & dosage | Multiple Sclerosis - drug therapy | Short term | Phosphates | Multiple sclerosis | Washouts | Nervous system | Malignancy | Modulators | Sphingosine 1-phosphate | Cell adhesion & migration | Lymphocytes | Phosphate | Risk assessment | Safety | Patient satisfaction | Heart diseases | Drug dosages | Edema | Lymphatic system | Effectiveness | Immunomodulation | Switching | Studies | Heart rate | Side effects | Titration
Journal Article